SCM
FOLD

Silvant Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Silvant Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,191
Closed -$159K – 316
2022
Q3 		$159K Hold
15,191
– – 0.01% 211
2022
Q2 		$163K Hold
15,191
– – 0.04% 164
2022
Q1 		$144K Hold
15,191
– – 0.03% 197
2021
Q4 		$175K Sell
15,191
-977
-6% -$10.9K 0.03% 189
2021
Q3 		$154K Hold
16,168
– – 0.03% 201
2021
Q2 		$156K Hold
16,168
– – 0.02% 204
2021
Q1 		$160K Hold
16,168
– – 0.03% 201
2020
Q4 		$373K Hold
16,168
– – 0.06% 148
2020
Q3 		$228K Buy
16,168
+5,442
+51% +$79.3K 0.04% 165
2020
Q2 		$162K Buy
+10,726
New +$131K 0.03% 185

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Silvant Capital Management's FOLD Position: Q4 2022 in Review

Silvant Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 15,191 shares — an estimated $159K sold.

Silvant Capital Management first reported a position in FOLD in Q2 2020 and held it in 10 quarters. The position peaked at $373K in Q4 2020. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

  • Silvant Capital Management reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Silvant Capital Management sold 15,191 Amicus Therapeutics shares in Q4 2022, an estimated $159K.
  • Silvant Capital Management first reported a position in Amicus Therapeutics in Q2 2020 and held it in 10 quarters.
  • Silvant Capital Management's Amicus Therapeutics position peaked at $373K in Q4 2020.
  • 230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Silvant Capital Management's 13F filing for Q4 2022, filed 23 Jan 2023.